Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01697839 · ClinicalTrials.gov registry record
Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients
A clinical trial of Multiple Myeloma and Peripheral Neuropathy, sponsored by Oncotherapeutics.
- Completed
- Registry status
- 110
- Enrollment target
- 3
- Study locations
NCT01697839: Completed study of Multiple Myeloma and Peripheral Neuropathy, sponsored by Oncotherapeutics.
NCT01697839 is a study of Multiple Myeloma and Peripheral Neuropathy that has completed, run by Oncotherapeutics. The registered enrollment target is 110 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (80% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01697839, a study of Multiple Myeloma and Peripheral Neuropathy, has completed, sponsored by Oncotherapeutics.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a prospective study investigating the relationship between vitamin D and peripheral neuropathy (PN) among multiple myeloma (MM) patients treated with either bortezomib or thalidomide. The study consists of a screening period of up to 14 days, followed by a single assessment visit to evaluate vitamin D levels, incidence and severity of PN, neuropathic pain, and markers of depression. Patient charts will also be utilized to assess the frequency of skeletal-related events.
Primary Outcome
Correlation of serum vitamin D levels to the incidence and severity of anti-myeloma treatment-induced PN/ neuropathic pain among MM patients previously exposed to bortezomib and/or thalidomide
Conditions Studied
Study Locations (3)
California
- Beaver Medical Group - Highland
- James R. Berenson M.D., Inc. - West Hollywood
Illinois
- Illinois Cancer Specialists - Hinsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2012-06 |
| Est. Completion | 2015-08 |
What the finished NCT01697839 record still lists
NCT01697839 is an observational study that tracks outcomes without assigning an intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 0 interventions.
NCT01697839 reports a single indexed study location in California, Illinois.
Frequently Asked Questions
What is clinical trial NCT01697839 about?
NCT01697839 is a clinical study titled "Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients". This is a prospective study investigating the relationship between vitamin D and peripheral neuropathy (PN) among multiple myeloma (MM) patients treated with either bortezomib or thalidomide. The study consists of a screening period of up to 14 days, followed by a single assessment visit to evaluate...
What is the current status of trial NCT01697839?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2012-06. Estimated completion is 2015-08.
What conditions does trial NCT01697839 study?
This clinical trial studies the following conditions: Multiple Myeloma, Peripheral Neuropathy.
Who is sponsoring clinical trial NCT01697839?
This trial is sponsored by Oncotherapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01697839 being conducted?
This trial has 3 study locations across California, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01697839's enrollment target sits among peer trials
110 158th of 438 higher than 280 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia